Gut Microbiomes in Patients With Metabolic Syndrome
Raktažodžiai
Santrauka
apibūdinimas
There is mounting evidence that the gut microbiome plays a vital role in health and wellbeing. In particular, population-association and mouse model studies have demonstrated that gut bacteria can be reproducibly linked to obesity and diabetes. There is, however, a lack of progress in translating current scientific knowledge to healthcare practices in part due to the strong influence of biogeography and demography on gut microbiomes. Another major knowledge gap in gut microbiomes is the ecology of gut viruses and their associations with MS despite having intimate relationships with human and bacterial hosts.
In this study, the investigators aim to assess variation in the gut microbiomes of patients with MS with reference to the healthy population in Hong Kong, and to explore gut microorganisms as predictive/diagnostic markers of MS and clinical outcomes associated with medical interventions. This will be achieved through studying microorganisms in the stools of participants. The investigators will use the 16S small subunit ribosomal RNA (16S rRNA) marker gene to create compositional profiles of the gut microbial community in healthy and individuals with MS to identify bacterial populations that are associated with the onset and progression of MS. A subset of samples will be selected for bulk DNA sequencing based on their stool community profiles and/or MS parameters to obtain genomic information of the microorganisms involved.
Participants who undergo intervention as part of their routine medical care for MS will be invited to provide stool samples following intervention. These stools will be used to profile gut microbial communities to investigate whether their compositions undergo changes reflective of medical intervention. Here, the aim is to investigate whether resolution of MS symptoms can be linked to alterations in gut microorganisms, and the hypothesis is that their profiles will more closely resemble healthy individuals following medical intervention.
Datos
Paskutinį kartą patikrinta: | 06/30/2018 |
Pirmasis pateikimas: | 03/22/2018 |
Numatytas registravimas pateiktas: | 04/02/2018 |
Pirmas paskelbtas: | 04/04/2018 |
Paskutinis atnaujinimas pateiktas: | 07/19/2018 |
Paskutinis atnaujinimas paskelbtas: | 07/22/2018 |
Faktinė studijų pradžios data: | 11/26/2017 |
Numatoma pirminio užbaigimo data: | 11/30/2021 |
Numatoma studijų užbaigimo data: | 11/30/2021 |
Būklė ar liga
Intervencija / gydymas
Drug: Metformin
Behavioral: lifestyle modification
Drug: Simvastatin 10mg
Drug: Amlodipine 5mg
Fazė
Rankų grupės
Ranka | Intervencija / gydymas |
---|---|
No metabolic syndrome Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation. | |
Metabolic syndrome- partial Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation. | |
Metabolic syndrome- full Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation. |
Tinkamumo kriterijai
Amžius, tinkami studijuoti | 35 Years Į 35 Years |
Tinkamos studijoms lytys | All |
Mėginių ėmimo metodas | Non-Probability Sample |
Priima sveikus savanorius | Taip |
Kriterijai | Inclusion Criteria: - Resident of Hong Kong Exclusion Criteria: - Major organ system impairment such as heart failure, renal failure, and severe impairment of respiratory function. - On long-term regular immunosuppressive therapy - Current or history of malignancy - Current or history of major gastrointestinal diseases, including inflammatory bowel disease, major gastrointestinal surgery - On medication for glucose or lipid control, such as metformin and statin |
Rezultatas
Pirminės rezultatų priemonės
1. Change in waist circumference at four weeks [four weeks in participants receiving drug intervention for metabolic syndrome]
2. Change in baseline systolic and diastolic blood pressure at four weeks [four weeks in participants receiving drug intervention for metabolic syndrome]
3. Change in blood triglyceride levels at four weeks [four weeks in participants receiving drug intervention for metabolic syndrome]
4. Change in high-density lipoprotein (HDL) cholesterol levels at four weeks [four weeks in participants receiving drug intervention for metabolic syndrome]
5. Change in fasting blood sugar levels at four weeks [four weeks in participants receiving drug intervention for metabolic syndrome]
6. Change in waist circumference at six months [six months in all participants with metabolic syndrome]
7. Change in baseline systolic and diastolic blood pressure at six months [six months in all participants with metabolic syndrome]
8. Change in blood triglyceride levels at six months [six months in all participants with metabolic syndrome]
9. Change in high-density lipoprotein (HDL) cholesterol levels at six months [six months in all participants with metabolic syndrome]
10. Change in fasting blood sugar levels at six months [six months in all participants with metabolic syndrome]